Insmed price target raised to $120 from $108 at RBC Capital

RBC Capital analyst Leonid Timashev raised the firm’s price target on Insmed (INSM) to $120 from $108 and keeps an Outperform rating on the shares after its Q2 results and discussion with its management. The firm continues to “sense enthusiasm” for a potential launch for brenso later this year, with everything on track for a potential approval on August 12th, the analyst tells investors in a research note.